Amiodarone Causes Acute Oxidant Lung Injury in Ventilated and Perfused Rabbit Lungs
- 30 June 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 12 (1) , 23-36
- https://doi.org/10.1097/00005344-198807000-00004
Abstract
Amiodarone (ADR), a new antiarrhythmic drug for life-threatening cardiac arrhythmias, causes pneumonitis or lung fibrosis in a sizeable minority of patients. The cause of lung damage is not known. We have shown that infusion of 10 mg amiodarone into the inflow circuit of ventilated and perfused rabbit lungs causes immediate increase in pulmonary artery pressure (mean ± SEM) (from 13.6 ± 1.2 to 40.6 ± 9.5 mm Hg, p < 0.01) and pulmonary edema with marked increase in the pulmonary generation of thromboxane and leukotrienes C4 and/or D4. Albumin (2 g%) in the perfusate prevents any increase in lung perfusion pressure or edema formation. When lung perfusion pressure increase is blocked with the combined cyclooxygenase and lipoxygenase inhibitor enolicam sodium (CG5391B, 35 μM in perfusate), significant lung edema still occurs after amiodarone, indicating that amiodarone causes increased alveolar-capillary membrane permeability. Addition of catalase (100 U/ml) or superoxide dismutase and catalase (100 U/ml each) to perfusate fails to protect from amiodarone lung injury. Immediate infusion of amiodarone (10 mg) into lungs ventilated with room air (ADR + RA) causes an increase in lung weight gain from baseline (ΔW) of 5.7 ± 1.5 g/min. Compared with ADR + RA, ventilation of lungs with 4% O2 (AW = 0.7 ± 0.3 g/min, p < 0.05). pretreatment of rabbits for 3 days with butylated hydroxyanisole (BHA, 100 mg/kg/day i.p., ΔW = 0.05 ± 0.02 g/min, p < 0.01), pretreatment of rabbits for 3 days with vitamin E (Vit E, 300 U/day orally, ΔW = 0.6 ± 0.2 g/min, p < 0.05), or addition of N-acetylcysteine to the lung perfusate (NAC, 5 mM, ΔW = 0.1 ± 0.08 g/min, p < 0.01) all protect from lung edema formation after amiodarone. Amiodarone (100 mg) also caused a marked increase in luminol-enhanced lung chemiluminescence, lung production of superoxide anion (O2−), and tissue levels of lung glutathione disulfide. These results suggest that amiodarone causes lung injury by an oxidant mechanism.Keywords
This publication has 39 references indexed in Scilit:
- Environmental Iodine Intake and Thyroid Dysfunction During Chronic Amiodarone TherapyAnnals of Internal Medicine, 1984
- Amiodarone Pulmonary ToxicityAnnals of Internal Medicine, 1982
- Control of refractory life-threatening ventricular tachyarrhythmias by amiodaroneAmerican Heart Journal, 1981
- Amiodarone KeratopathyArchives of Ophthalmology (1950), 1981
- Hydroperoxide-induced chemiluminescence of the perfused lungBiochemical Journal, 1980
- Chemiluminescent measurement of free radicals and antioxidant molecular-protection inside living rat-mitochondriaExperimental Gerontology, 1980
- Control of refractory cardiac arrhythmias with amiodaroneArchives of internal medicine (1960), 1979
- Neuromyopathy during chronic amiodarone treatmentZeitschrift für Neurologie, 1979
- Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.Journal of Clinical Investigation, 1976
- Superoxide dismutase: Improved assays and an assay applicable to acrylamide gelsAnalytical Biochemistry, 1971